* SDZ SER-082: a mixed 5-HT2B/C antagonist* EGIS-7625: high selectivity over 5-HT2A* PRX-08066* SB-200,646* SB-204,741* SB-206,553: mixed 5-HT2B/C antagonist and PAM at α7 nAChR* SB-215,505* SB-228,357* LY-266,097* LY-272,015==Possible applications==5-HT2B antagonists have previously been proposed as treatment for migraine headaches, and RS-127,445 was trialled in humans up to Phase I for this indication, but development was not continued.
* SDZ SER-082: a mixed 5-HT2B/C antagonist* EGIS-7625: high selectivity over 5-HT2A* PRX-08066* SB-200,646* SB-204,741* SB-206,553: mixed 5-HT2B/C antagonist and PAM at α7 nAChR* SB-215,505* SB-228,357* LY-266,097* LY-272,0155-HT2B antagonists have previously been proposed as treatment for migraine headaches, and RS-127,445 was trialled in humans up to Phase I for this indication, but development was not continued.